Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2016 April;107(2) > Minerva Medica 2016 April;107(2):114-22

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

 

Minerva Medica 2016 April;107(2):114-22

 REVIEWS

Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering

Patrizia ROMUALDI, Sanzio CANDELETTI

Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy

The management of cancer pain presents manifold challenges: even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP). The characteristics of BTcP are a rapid onset, a short duration, and a severe intensity. An innovative sublingual fentanyl citrate formulation (Vellofent®) has been developed to target BTcP. The new formulation allows to increase the solubility of fentanyl and to provide optimal oromucosal conditions for rapid drug absorption, thus featuring a shorter time to onset of pain relief (from 6 minutes post-administration).

language: English


FULL TEXT  REPRINTS

top of page